通过天眼查大数据分析，丽珠医药集团股份有限公司共对外投资了47家企业，参与招投标项目481次， 知识产权方面有商标信息623条，专利信息343条，此外企业还拥有行政许可74个。 来源：金融界 金融界消息 截至2025年7月31日收盘，丽珠集团（000513）报收于41.95元，上涨0.22%，换手率 2.76%，成交量16.12万手，成交金额6.77亿元。 资金流向方面，今日主力资金净流入4224.13万元，占比成交额6.24%。其中，超大单净流入1599.15万 元、占成交额2.36%，大单净流入2624.98万元、占成交额3.88%，中单净流出流入2925.29万元、占成交 额4.32%，小单净流出7149.42万元、占成交额10.57%。 丽珠集团最新一期业绩显示，截至2025一季报，公司营业总收入31.81亿元、同比减少1.92%，归属净利 润6.37亿元，同比增长4.75%，扣非净利润6.19亿元，同比增长4.82%，流动比率2.276、速动比率 2.013、资产负债率37.21%。 天眼查商业履历信息显示，丽珠医药集团股份有限公司，成立于1985年，位于珠海市，是一家以从事医 药制造业为主的企业。 ...

中国经济网北京7月31日讯 科兴制药（688136.SH）昨晚发布股东询价转让计划书。 2020年12月14日，科兴制药在上交所科创板上市，发行股票数量为4967.53万股，发行价格为22.33元/ 股，保荐机构（主承销商）为中信建投证券，保荐代表人为徐新岳、张星明。 科兴制药首次公开发行股票募集资金总额为11.09亿元，实际募集资金净额为9.95亿元。科兴制药实际募 资净额比原拟募资额少7.10亿元。科兴制药于2020年12月7日披露的招股说明书显示，该公司原拟募资 17.05亿元，拟分别用于药物生产基地改扩建项目、研发中心升级建设项目、信息管理系统升级建设项 目和补充流动资金。 科兴制药首次公开发行股票的发行费用（含税）总额为1.15亿元，其中，保荐及承销费用9385.58万元。 天眼查APP显示，科兴生物制药股份有限公司(曾用名：山东科兴生物制品有限公司)，成立于1997年， 位于山东省济南市，是一家以从事医药制造业为主的企业。企业注册资本19964.225万人民币。 本次拟参与科兴制药首发前股东询价转让（以下简称"本次询价转让"）的股东为深圳科益医药控股有限 公司。出让方拟转让股份的总数为6,037, ...

Core Viewpoint - The article highlights the increasing trend of mid-term dividends among companies listed on the Shenzhen Stock Exchange, with a total dividend amount exceeding 10.25 billion yuan for the first half of 2025, indicating a shift towards more frequent shareholder returns [1][4][2]. Group 1: Mid-term Dividend Trends - As of July 30, 2025, 14 companies in the Shenzhen market have announced mid-term profit distribution plans, with a total dividend amount of 10.251 billion yuan [4]. - The trend of multiple dividends per year is emerging, driven by companies' confidence in their annual performance and industry outlook, as well as regulatory encouragement for companies to establish long-term dividend plans [4][6]. - Eight companies are implementing mid-term dividends for the first time, including Haida Group, which plans to distribute 0.2 yuan per share, totaling 333 million yuan [4]. Group 2: Regulatory and Investor Influence - The Shenzhen Stock Exchange has been actively promoting the establishment of annual dividend plans among listed companies, encouraging them to adopt a more frequent dividend distribution approach [4][6]. - There is a growing emphasis on stable returns for investors, with 216 companies in 2024 and an additional 165 in 2025 announcing long-term shareholder dividend return plans [6][7]. Group 3: Leading Companies and Their Impact - Major companies with strong financial health, such as Ningde Times and Mindray Medical, are leading the way in mid-term dividends, with Ningde Times announcing a dividend of 4.573 billion yuan [11]. - The "leading goose effect" is evident as large-cap companies set an example for others, enhancing overall investor confidence in the market [9][11].

Group 1 - Beijing Yimiao Shenzhou Biopharmaceutical Co., Ltd. (referred to as "Yimiao Shenzhou") completed its IPO counseling record with the Beijing Securities Regulatory Bureau, aiming for an IPO on the Sci-Tech Innovation Board, with CITIC Securities as the counseling institution [1] - The company was established on April 14, 2015, with a registered capital of 30 million RMB, focusing on gene cell drugs for the treatment of malignant tumors [1] - The controlling shareholder is He Ting, who directly and indirectly controls 21.92% of the company's shares, and he graduated from Tsinghua University with a background in cancer biology [1] Group 2 - The company has undertaken over ten national and provincial scientific research projects, collaborating with top hospitals such as Beijing Cancer Hospital, Tsinghua Changgung Hospital, Peking Union Medical College Hospital, and others for CAR-T drug clinical research [2] - Yimiao Shenzhou has been recognized as a national high-tech enterprise, a postdoctoral research workstation, a Beijing engineering research center, a specialized and innovative enterprise in Beijing, and a CAR-T joint research and development center [2]

企业名称泽牧惟科（南通）生物制药有限公司法定代表人钟天翼注册资本200万人民币国标行业制造业 >医药制造业>化学药品制剂制造地址江苏省南通市崇川区唐闸镇街道永福路109号7幢401室企业类型有 限责任公司营业期限2025-7-30至无固定期限登记机关南通市崇川区行政审批局 来源：金融界 天眼查App显示，近日，泽牧惟科（南通）生物制药有限公司成立，法定代表人为钟天翼，注册资本 200万人民币，由苏州慧疗生物医药科技有限公司全资持股。 序号股东名称持股比例1苏州慧疗生物医药科技有限公司100% 经营范围含许可项目：药品生产；药品委托生产；药品进出口；药品零售；兽药生产；兽药经营；药品 批发；药用辅料生产；药用辅料销售（依法须经批准的项目，经相关部门批准后方可开展经营活动，具 体经营项目以审批结果为准）医学研究和试验发展；科技推广和应用服务；技术服务、技术开发、技术 咨询、技术交流、技术转让、技术推广；自然科学研究和试验发展（除依法须经批准的项目外，凭营业 执照依法自主开展经营活动） ...

通过天眼查大数据分析，浙江我武生物科技股份有限公司共对外投资了6家企业，参与招投标项目337 次，知识产权方面有商标信息38条，专利信息20条，此外企业还拥有行政许可63个。 来源：金融界 资金流向方面，今日主力资金净流出5820.70万元，占比成交额13.26%。其中，超大单净流出2538.91万 元、占成交额5.78%，大单净流出3281.78万元、占成交额7.48%，中单净流出流出993.77万元、占成交 额2.26%，小单净流入6814.46万元、占成交额15.52%。 我武生物最新一期业绩显示，截至2025一季报，公司营业总收入2.28亿元、同比增长5.65%，归属净利 润7434.21万元，同比减少3.71%，扣非净利润7361.84万元，同比增长1.48%，流动比率19.060、速动比 率18.379、资产负债率5.42%。 天眼查商业履历信息显示，浙江我武生物科技股份有限公司，成立于2002年，位于湖州市，是一家以从 事医药制造业为主的企业。企业注册资本52358.4万人民币，实缴资本52358.4万人民币。公司法定代表 人为胡赓熙。 金融界消息 截至2025年7月30日收盘，我武生物（300 ...

Group 1 - The core viewpoint of the news is that Shandong Lukang Pharmaceutical Co., Ltd. has shown a mixed financial performance in the latest quarter, with a decline in total revenue but an increase in net profit [1] - As of July 30, 2025, the company's stock price closed at 10.59 yuan, down 1.3%, with a turnover rate of 7.03% and a trading volume of 631,900 hands, amounting to 672 million yuan [1] - The company's latest quarterly report indicates total operating revenue of 1.674 billion yuan, a year-on-year decrease of 6.95%, while net profit attributable to shareholders reached 78.5976 million yuan, a year-on-year increase of 16.77% [1] Group 2 - The company has a current ratio of 1.279, a quick ratio of 0.862, and a debt-to-asset ratio of 54.65% [1] - Shandong Lukang Pharmaceutical has made investments in 17 enterprises and participated in 5,000 bidding projects, showcasing its active engagement in the market [2] - The company holds 187 trademark registrations and 240 patents, along with 313 administrative licenses, indicating a strong intellectual property portfolio [2]

金融界消息 截至2025年7月30日收盘，圣湘生物（688289）报收于22.26元，下跌1.81%，换手率 1.63%，成交量9.42万手，成交金额2.11亿元。 资金流向方面，今日主力资金净流出4389.43万元，占比成交额20.82%。其中，超大单净流出2758.48万 元、占成交额13.08%，大单净流出1630.95万元、占成交额7.73%，中单净流出流入1222.60万元、占成 交额5.8%，小单净流入3166.82万元、占成交额15.02%。 天眼查商业履历信息显示，圣湘生物科技股份有限公司，成立于2008年，位于长沙市，是一家以从事医 药制造业为主的企业。企业注册资本57938.8006万人民币，实缴资本12648.8642万人民币。公司法定代 表人为戴立忠。 通过天眼查大数据分析，圣湘生物科技股份有限公司共对外投资了27家企业，参与招投标项目1046次， 知识产权方面有商标信息387条，专利信息467条，此外企业还拥有行政许可311个。 来源：金融界 圣湘生物最新一期业绩显示，截至2025一季报，公司营业总收入4.75亿元、同比增长21.62%，归属净利 润9173.55万元，同比增长13. ...

Group 1 - The company announced that its controlling shareholder, Ningbo Yinyi Holdings Co., Ltd., is planning a share transfer that may lead to a change in the controlling shareholder and actual controller [2] - The company's stock was suspended from trading starting July 31, with an expected suspension period of no more than two trading days [2] - On July 30, the company's stock price hit the daily limit, closing at 8.02 yuan per share, with a market capitalization exceeding 2.9 billion yuan [2] Group 2 - In 2024, the company achieved operating revenue of 212 million yuan, a year-on-year increase of 12.81%, and a net profit of 79.25 million yuan, compared to a net loss of 11.56 million yuan in 2023 [2] - The strong performance was attributed to robust growth in the pharmaceutical intermediates business and steady improvement in the urea business, although challenges remain in cost control and market expansion [2] - For 2025, the company plans to expand its existing product supply chain, enhance management efficiency, increase R&D investment, and support the strategic transformation of its main business, Nansong Pharmaceutical [3] Group 3 - In Q1 2025, the company reported operating revenue of 40.83 million yuan, a year-on-year decline of 34.05%, and a net profit of 1.36 million yuan, compared to a net loss of 116,000 yuan in the same period last year [3] - The company aims to overcome challenges such as significant fluctuations in the urea market and the diminishing brand effect of its urea products [3]

资金流向方面，今日主力资金净流出3686.75万元，占比成交额4.99%。其中，超大单净流出4517.51万 元、占成交额6.11%，大单净流入830.77万元、占成交额1.12%，中单净流出流入2257.57万元、占成交 额3.05%，小单净流入1429.18万元、占成交额1.93%。 通过天眼查大数据分析，江苏诺泰澳赛诺生物制药股份有限公司共对外投资了13家企业，参与招投标项 目192次，知识产权方面有商标信息13条，专利信息123条，此外企业还拥有行政许可397个。 来源：金融界 ST诺泰最新一期业绩显示，截至2025一季报，公司营业总收入5.66亿元、同比增长58.96%，归属净利润 1.53亿元，同比增长130.10%，扣非净利润1.52亿元，同比增长131.79%，流动比率1.062、速动比率 0.732、资产负债率47.86%。 天眼查商业履历信息显示，江苏诺泰澳赛诺生物制药股份有限公司，成立于2009年，位于连云港市，是 一家以从事医药制造业为主的企业。企业注册资本21318.38万人民币，实缴资本15690.785万人民币。公 司法定代表人为童梓权。 金融界消息 截至2025年7月30日收盘 ...